{
  "ticker": "TBPH",
  "company_name": "Theravance Biopharma, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02578082",
      "title": "Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Renal Impairment",
      "start_date": "2015-12",
      "completion_date": "2016-05",
      "enrollment": 0,
      "sponsor": "Mylan Inc."
    },
    {
      "nct_id": "NCT02459080",
      "title": "Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Chronic Obstructive Pulmonary Disease (COPD)",
      "start_date": "2015-09",
      "completion_date": "2016-09",
      "enrollment": 0,
      "sponsor": "Mylan Inc."
    },
    {
      "nct_id": "NCT02518139",
      "title": "A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Chronic Obstructive Pulmonary Disease (COPD)",
      "start_date": "2015-09",
      "completion_date": "2017-06",
      "enrollment": 0,
      "sponsor": "Mylan Inc."
    },
    {
      "nct_id": "NCT01704404",
      "title": "7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "COPD",
      "start_date": "2012-12",
      "completion_date": "2013-12",
      "enrollment": 0,
      "sponsor": "Mylan Inc."
    },
    {
      "nct_id": "NCT02772159",
      "title": "TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Chronic Obstructive Pulmonary Disease (COPD)",
      "start_date": "2015-06",
      "completion_date": "2016-04",
      "enrollment": 0,
      "sponsor": "Mylan Inc."
    },
    {
      "nct_id": "NCT03064113",
      "title": "Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Chronic Obstructive Pulmonary Disease, COPD",
      "start_date": "2011-05",
      "completion_date": "2011-10",
      "enrollment": 0,
      "sponsor": "Mylan Inc."
    },
    {
      "nct_id": "NCT03095456",
      "title": "Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)",
      "start_date": "2017-03-27",
      "completion_date": "2017-11-25",
      "enrollment": 0,
      "sponsor": "Mylan Inc."
    },
    {
      "nct_id": "NCT03573817",
      "title": "A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Chronic Obstructive Pulmonary Disease (COPD)",
      "start_date": "2018-05-31",
      "completion_date": "2018-09-25",
      "enrollment": 0,
      "sponsor": "Mylan Inc."
    },
    {
      "nct_id": "NCT02040792",
      "title": "A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "COPD",
      "start_date": "2014-05",
      "completion_date": "2014-08",
      "enrollment": 0,
      "sponsor": "Mylan Inc."
    },
    {
      "nct_id": "NCT02820311",
      "title": "Thorough QT (TQT) Study of TD-4208 in Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Cardiac Repolarization in Healthy Subjects",
      "start_date": "2016-05",
      "completion_date": "2016-07",
      "enrollment": 0,
      "sponsor": "Mylan Inc."
    }
  ],
  "summary": {
    "total_trials": 15,
    "by_phase": {
      "PHASE1": 4,
      "PHASE3": 5,
      "PHASE2": 5,
      "PHASE4": 1
    },
    "by_status": {
      "COMPLETED": 15
    },
    "active_trials": 0,
    "completed_trials": 15,
    "conditions": [
      "COPD",
      "COPD, Acute Respiratory Failure",
      "Cardiac Repolarization in Healthy Subjects",
      "Chronic Obstructive Pulmonary Disease",
      "Chronic Obstructive Pulmonary Disease (COPD)",
      "Chronic Obstructive Pulmonary Disease, COPD",
      "Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)",
      "Hepatic Impairment",
      "Renal Impairment"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:44:59.771279",
    "search_query": "Theravance Biopharma, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Theravance+Biopharma,+Inc."
  }
}